{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:49:26Z","timestamp":1784198966833,"version":"3.55.0"},"reference-count":34,"publisher":"American Diabetes Association","issue":"2","license":[{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"DOI":"10.13039\/501100003092","name":"Diabetes Fonds","doi-asserted-by":"publisher","award":["459001019"],"award-info":[{"award-number":["459001019"]}],"id":[{"id":"10.13039\/501100003092","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"<jats:p>Glucagon-like peptide 1 receptor (GLP-1R) agonists fail to reduce weight or improve glucose control in a sizable minority of individuals with type 2 diabetes. We hypothesized that stimulation of the hypothalamic-pituitary-adrenal (HPA) axis by GLP-1R agonists, thus inducing cortisol secretion, could explain this unresponsiveness to GLP-1R agonists. To assess the effects of GLP-1R agonist treatment on the HPA axis, we selected 10 individuals with type 2 diabetes with (n = 5 women and 5 men) and nine without (n = 4 and 5) an adequate response to GLP-1R agonists and used [68Ga]Ga-NODAGA-exendin-4 positron emission tomography\/computed tomography to quantify GLP-1R expression in the pituitary. Oral glucose tolerance and 24-h urinary cortisol excretion were measured in all participants. Pituitary tracer uptake was observed in all participants, with no significant difference between responders and nonresponders. Pituitary tracer uptake correlated with the area under the curve for ACTH, urinary cortisol-to-creatinine ratio, and age. Interestingly, men had higher pituitary tracer uptake than women. In conclusion, this study does not indicate a role for pituitary GLP-1R expression or HPA axis stimulation in the difference in treatment response to GLP-1R agonists among individuals with type 2 diabetes. The findings of substantial pituitary GLP-1R expression and the significant sex differences require further research.<\/jats:p>\n               <jats:sec>\n                  <jats:title>Article Highlights<\/jats:title>\n                  <jats:p>It is unclear why some individuals with type 2 diabetes are unresponsive to treatment with glucagon-like peptide 1 receptor (GLP-1R) agonists, but hypothalamic-pituitary-adrenal (HPA) axis activation could play a role. We used [68Ga]Ga-NODAGA-exendin-4 positron emission tomography\/computed tomography to compare pituitary GLP-1R expression between responders and nonresponders to treatment with GLP-1R agonists. Pituitary GLP-1R expression and HPA axis activation did not differ between responders and nonresponders to GLP-1R agonist treatment. In addition, pituitary radiolabeled exendin uptake was markedly higher in men than in women. Further study is required to explain treatment differences and understand sex differences in pituitary radiolabeled exendin uptake.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/db24-0463","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T21:23:04Z","timestamp":1732051384000},"page":"212-222","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":7,"title":["Activation of the HPA Axis Does Not Explain Nonresponsiveness to GLP-1R Agonist Treatment in Individuals With Type 2 Diabetes"],"prefix":"10.2337","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7597-8170","authenticated-orcid":false,"given":"Sevilay","family":"Tokg\u00f6z","sequence":"first","affiliation":[{"name":"1Department of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marti","family":"Boss","sequence":"additional","affiliation":[{"name":"1Department of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands"},{"name":"2Netherlands Heart Institute, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodorus J.P.","family":"Jansen","sequence":"additional","affiliation":[{"name":"1Department of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Meijer","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathelijne","family":"Frielink","sequence":"additional","affiliation":[{"name":"1Department of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianne C.","family":"van Bon","sequence":"additional","affiliation":[{"name":"4Department of Internal Medicine, Rijnstate Hospital, Arnhem, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cees J.","family":"Tack","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastiaan E.","family":"de Galan","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands"},{"name":"5Department of Internal Medicine, Maastricht University Medical Center, Maastricht, the Netherlands"},{"name":"6Cardiovascular Research Institute Maastricht School for Cardiovascular Disease, Maastricht University, Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gotthardt","sequence":"additional","affiliation":[{"name":"1Department of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2024,11,19]]},"reference":[{"key":"2025012119510473200_B1","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"key":"2025012119510473200_B2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2337\/cd23-as01","article-title":"Standards of Care in Diabetes\u20142023. Abridged for primary care providers","volume":"41","author":"American Diabetes Association","year":"2022","journal-title":"Clin Diabetes"},{"key":"2025012119510473200_B3","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"2025012119510473200_B4","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/dom.12824","article-title":"Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials","volume":"19","author":"Bettge","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2025012119510473200_B5","doi-asserted-by":"crossref","first-page":"814770","DOI":"10.3389\/fendo.2021.814770","article-title":"Gut microbial signatures for glycemic responses of GLP-1 receptor agonists in type 2 diabetic patients: a pilot study","volume":"12","author":"Tsai","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025012119510473200_B6","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3390\/jpm12030424","article-title":"Clinical and genetic predictors of glycemic control and weight loss response to liraglutide in patients with type 2 diabetes","volume":"12","author":"Kyriakidou","year":"2022","journal-title":"J Pers Med"},{"key":"2025012119510473200_B7","doi-asserted-by":"crossref","first-page":"162718","DOI":"10.1155\/2015\/162718","article-title":"Determining predictors of early response to exenatide in patients with type 2 diabetes mellitus","volume":"2015","author":"Khan","year":"2015","journal-title":"J Diabetes Res"},{"key":"2025012119510473200_B8","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1038\/s41588-023-01462-3","article-title":"GWAS of random glucose in 476,326 individuals provide insights into diabetes pathophysiology, complications and treatment stratification","volume":"55","author":"Lagou","year":"2023","journal-title":"Nat Genet"},{"key":"2025012119510473200_B9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S2213-8587(22)00340-0","article-title":"Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials","volume":"11","author":"Dawed","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025012119510473200_B10","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2337\/dc15-0258","article-title":"Markers of \u03b2-cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes","volume":"39","author":"Jones","year":"2016","journal-title":"Diabetes Care"},{"key":"2025012119510473200_B11","first-page":"454","article-title":"Sex differences in response to treatment with glucagon-like peptide 1 receptor agonists: opportunities for a tailored approach to diabetes and obesity care","volume":"12","author":"Rentzeperi","year":"2022","journal-title":"J\u00a0Pers Med"},{"key":"2025012119510473200_B12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2967\/jnumed.119.228627","article-title":"PET-based human dosimetry of 68Ga-NODAGA-exendin-4, a tracer for \u03b2-cell imaging","volume":"61","author":"Boss","year":"2020","journal-title":"J Nucl Med"},{"key":"2025012119510473200_B13","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2967\/jnumed.121.262327","article-title":"68Ga-NODAGA-exendin-4 PET\/CT improves the detection of focal congenital hyperinsulinism","volume":"63","author":"Boss","year":"2022","journal-title":"J Nucl Med"},{"key":"2025012119510473200_B14","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.3390\/brainsci11121647","article-title":"Brain imaging of the GLP-1 receptor in obesity using 68Ga-NODAGA-exendin-4 PET","volume":"11","author":"Deden","year":"2021","journal-title":"Brain Sci"},{"key":"2025012119510473200_B15","doi-asserted-by":"crossref","first-page":"100972","DOI":"10.1016\/j.yfrne.2021.100972","article-title":"How exposure to chronic stress contributes to the development of type 2 diabetes: a complexity science approach","volume":"65","author":"Merabet","year":"2022","journal-title":"Front Neuroendocrinol"},{"key":"2025012119510473200_B16","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.psyneuen.2009.09.017","article-title":"CRH-stimulated cortisol release and food intake in healthy, non-obese adults","volume":"35","author":"George","year":"2010","journal-title":"Psychoneuroendocrinology"},{"key":"2025012119510473200_B17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/nyas.13217","article-title":"Cortisol dysregulation: the bidirectional link between stress, depression, and type 2 diabetes mellitus","volume":"1391","author":"Joseph","year":"2017","journal-title":"Ann N Y Acad Sci"},{"key":"2025012119510473200_B18","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1210\/en.2009-0915","article-title":"GLP-1(7-36)-amide and exendin-4 stimulate the HPA axis in rodents and humans","volume":"151","author":"Gil-Lozano","year":"2010","journal-title":"Endocrinology"},{"key":"2025012119510473200_B19","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.2337\/diacare.21.12.2191","article-title":"Correct homeostasis model assessment (HOMA) evaluation uses the computer program","volume":"21","author":"Levy","year":"1998","journal-title":"Diabetes Care"},{"key":"2025012119510473200_B20","unstructured":"University of Oxford\n          . HOMA calculator. Accessed 2 January 2024. Available from https:\/\/www.dtu.ox.ac.uk\/homacalculator\/"},{"key":"2025012119510473200_B21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/978-1-0716-2807-2_9","article-title":"Protocol for clinical GLP-1 receptor PET\/CT imaging with [68Ga]Ga-NODAGA-exendin-4","volume":"2592","author":"Tokg\u00f6z","year":"2023","journal-title":"Methods Mol Biol"},{"key":"2025012119510473200_B22","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1055\/a-1498-7098","article-title":"A GLP-1 receptor agonist inhibits aldosterone release in healthy volunteers","volume":"53","author":"Heinla","year":"2021","journal-title":"Horm Metab Res"},{"key":"2025012119510473200_B23","doi-asserted-by":"crossref","first-page":"E1105","DOI":"10.1152\/ajpendo.00529.2012","article-title":"Effects of prolonged exendin-4 administration on hypothalamic-pituitary-adrenal axis activity and water balance","volume":"304","author":"Gil-Lozano","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2025012119510473200_B24","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3390\/ph15070904","article-title":"Bolus injection of liraglutide raises plasma glucose in normal rats by activating glucagon-like peptide 1 receptor in the brain","volume":"15","author":"Hsu","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"2025012119510473200_B25","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1210\/jc.2018-01420","article-title":"Effects of glucagon-like peptide-1 receptor agonists on hypothalamic-pituitary-adrenal axis in healthy volunteers","volume":"104","author":"Winzeler","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2025012119510473200_B26","first-page":"593","article-title":"Prolonged exendin-4 administration stimulates pituitary-adrenocortical axis of normal and streptozotocin-induced diabetic rats","volume":"12","author":"Malendowicz","year":"2003","journal-title":"Int J Mol Med"},{"key":"2025012119510473200_B27","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.endoen.2016.04.005","article-title":"Baseline ALT levels as a marker of glycemic response to treatment with GLP-1 receptor agonists","volume":"63","author":"Gimeno-Orna","year":"2016","journal-title":"Endocrinolog\u00eda y Nutrici\u00f3n (English Edition)"},{"key":"2025012119510473200_B28","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/1758-5996-6-110","article-title":"Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes","volume":"6","author":"Imai","year":"2014","journal-title":"Diabetol Metab Syndr"},{"key":"2025012119510473200_B29","doi-asserted-by":"crossref","first-page":"9454","DOI":"10.3390\/ijms22179454","article-title":"Circulating microRNAs signature for predicting response to GLP1-RA therapy in type 2 diabetic patients: a pilot study","volume":"22","author":"Formichi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025012119510473200_B30","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00213-023-06367-x","article-title":"Sex-dependent divergence in the effects of GLP-1 agonist exendin-4 on alcohol reinforcement and reinstatement in C57BL\/6J mice","volume":"240","author":"D\u00edaz-Megido","year":"2023","journal-title":"Psychopharmacology (Berl)"},{"key":"2025012119510473200_B31","doi-asserted-by":"crossref","first-page":"69-LB","DOI":"10.2337\/db23-69-LB","article-title":"Sex-specific dynamics of GLP-1R and GIPR expression in the hypothalamus and the amygdala of mice","volume":"72","author":"Hofmann","year":"2023","journal-title":"Diabetes"},{"key":"2025012119510473200_B32","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cmet.2011.08.009","article-title":"Distinct hypothalamic neurons mediate estrogenic effects on energy homeostasis and reproduction","volume":"14","author":"Xu","year":"2011","journal-title":"Cell Metab"},{"key":"2025012119510473200_B33","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/nm.3009","article-title":"Targeted estrogen delivery reverses the metabolic syndrome","volume":"18","author":"Finan","year":"2012","journal-title":"Nat Med"},{"key":"2025012119510473200_B34","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13293-016-0059-9","article-title":"Sex and estrogens alter the action of glucagon-like peptide-1 on reward","volume":"7","author":"Richard","year":"2016","journal-title":"Biol Sex Differ"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/74\/2\/212\/789785\/db240463.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/74\/2\/212\/789785\/db240463.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T19:51:18Z","timestamp":1737489078000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/74\/2\/212\/157480\/Activation-of-the-HPA-Axis-Does-Not-Explain"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,19]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,11,19]]},"published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db24-0463","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,19]]}}}